Characteristic | Wild-type | Alpha variant | Delta variant | Other variants | Not tested/ indeterminate | Total | p value |
---|---|---|---|---|---|---|---|
No. of people with a positive SARS-CoV-2 test | 92 427 | 182 020 | 3708 | 32 164 | 48 760 | 359 079 | – |
Age, yr, n (%) | |||||||
< 18 | 19 884 (21.5) | 31 875 (17.5) | 702 (18.9) | 5439 (16.9) | 8449 (17.3) | 66 349 (18.5) | < 0.0001 |
18–39 | 31 017 (33.6) | 69 101 (38.0) | 1409 (38.0) | 12 440 (38.7) | 18 944 (38.9) | 132 911 (37) | |
40–65 | 34 832 (37.7) | 67 697 (37.2) | 1290 (34.8) | 11 652 (36.2) | 16 551 (33.9) | 132 022 (36.8) | |
> 65 | 6694 (7.2) | 13 347 (7.3) | 307 (8.3) | 2633 (8.2) | 4816 (9.9) | 27 797 (7.7) | |
Age, yr, median (IQR) | |||||||
Alberta | 32 (18–47) | 33 (20–47) | 32 (20–45) | 35 (22–48) | NA | 33 (19–47) | < 0.0001 |
Ontario | 36 (23–54) | 36 (23–52) | 35 (22–52) | 36 (22–52) | 36 (22–53) | 36 (23–52) | < 0.0001 |
Male, n (%) | 47 217 (51.1) | 92 315 (50.7) | 1898 (51.2) | 16 700 (51.9) | 24 492 (50.2) | 182 622 (50.9) | < 0.0001 |
Rural resident, n (%) | 9317 (10.1) | 9856 (5.4) | 301 (8.1) | 1608 (5) | 3034 (6.2) | 24 116 (6.7) | < 0.0001 |
Deprivation Index, n (%) | |||||||
Missing | 3902 (4.2) | 3231 (1.8) | 69 (1.9) | 482 (1.5) | 1243 (2.5) | 8927 (2.5) | < 0.0001 |
Q1 (least deprived) | 15 183 (16.4) | 32 650 (17.9) | 589 (15.9) | 5407 (16.8) | 8882 (18.2) | 62 711 (17.5) | |
Q2 | 15 997 (17.3) | 34 327 (18.9) | 621 (16.7) | 5807 (18.1) | 8950 (18.4) | 65 702 (18.3) | |
Q3 | 17 047 (18.4) | 34 328 (18.9) | 664 (17.9) | 6001 (18.7) | 8845 (18.1) | 66 885 (18.6) | |
Q4 | 16 983 (18.4) | 36 044 (19.8) | 747 (20.1) | 6576 (20.4) | 9289 (19.1) | 69 639 (19.4) | |
Q5 (most deprived) | 23 315 (25.2) | 41 440 (22.8) | 1018 (27.5) | 7891 (24.5) | 11 551 (23.7) | 85 215 (23.7) | |
In a long-term care facility, n (%) | 326 (0.4) | 165 (0.1) | 32 (0.9) | 53 (0.2) | 250 (0.5) | 826 (0.2) | < 0.0001 |
Charlson Comorbidity Index score, n (%) | |||||||
0/missing | 87 775 (95) | 169 547 (93.1) | 3368 (90.8) | 29 602 (92) | 43 821 (89.9) | 334 113 (93) | < 0.0001 |
1 | 943 (1) | 1475 (0.8) | 35 (0.9) | 263 (0.8) | 621 (1.3) | 3337 (0.9) | |
2 | 610 (0.7) | 1081 (0.6) | 29 (0.8) | 212 (0.7) | 402 (0.8) | 2334 (0.6) | |
3+ | 3099 (3.4) | 9917 (5.4) | 276 (7.4) | 2087 (6.5) | 3916 (8) | 19 295 (5.4) | |
Specific comorbidities, n (%) | |||||||
COPD or asthma | 360 (0.4) | 534 (0.3) | 7 (0.2) | 113 (0.4) | 193 (0.4) | 1207 (0.3) | < 0.0001 |
Other chronic lung disease (non-COPD/asthma) | 16 (0) | 23 (0) | 1–5* | 1–5* | 10 (0) | 56 (0) | 0.02 |
Congestive heart failure | 331 (0.4) | 577 (0.3) | 12 (0.3) | 113 (0.4) | 242 (0.5) | 1275 (0.4) | < 0.0001 |
Hypertension | 1001 (1.1) | 1936 (1.1) | 46 (1.2) | 351 (1.1) | 719 (1.5) | 4053 (1.1) | < 0.0001 |
Diabetes mellitus | 1124 (1.2) | 1935 (1.1) | 52 (1.4) | 366 (1.1) | 754 (1.5) | 4231 (1.2) | < 0.0001 |
CAD (including previous MI, CABG or PCI/stent) | 443 (0.5) | 919 (0.5) | 22 (0.6) | 174 (0.5) | 343 (0.7) | 1901 (0.5) | < 0.0001 |
Peripheral vascular disease | 83 (0.1) | 147 (0.1) | 3 (0.1) | 36 (0.1) | 66 (0.1) | 335 (0.1) | 0.008 |
Cerebrovascular disease (previous stroke/TIA) | 185 (0.2) | 312 (0.2) | 8 (0.2) | 54 (0.2) | 140 (0.3) | 699 (0.2) | < 0.0001 |
Atrial fibrillation/flutter | 330 (0.4) | 535 (0.3) | 18 (0.5) | 110 (0.3) | 263 (0.5) | 1256 (0.3) | < 0.0001 |
Ventricular arrhythmias | 31 (0) | 63 (0) | 1–5* | 17 (0.1) | 17 (0) | 130 (0) | 0.5 |
Renal disease | 181 (0.2) | 348 (0.2) | 1–5* | 53 (0.2) | 139 (0.3) | 725 (0.2) | 0.0002 |
Cancer | 417 (0.5) | 831 (0.5) | 18 (0.5) | 169 (0.5) | 317 (0.7) | 1752 (0.5) | < 0.0001 |
Peptic ulcer disease | 72 (0.1) | 124 (0.1) | 1–5* | 27 (0.1) | 55 (0.1) | 282 (0.1) | 0.04 |
Liver disease | 173 (0.2) | 198 (0.1) | 8 (0.2) | 43 (0.1) | 122 (0.3) | 544 (0.2) | < 0.0001 |
Dementia | 181 (0.2) | 212 (0.1) | 9 (0.2) | 51 (0.2) | 168 (0.3) | 621 (0.2) | < 0.0001 |
Vaccination status, n (%) | |||||||
Fully vaccinated | 334 (0.4) | 925 (0.5) | 111 (3) | 195 (0.6) | 935 (1.9) | 2500 (0.7) | < 0.0001 |
Partially vaccinated | 3823 (4.1) | 11 722 (6.4) | 1010 (27.2) | 2100 (6.5) | 3723 (7.6) | 22 378 (6.2) | |
Unvaccinated | 88 270 (95.5) | 169 373 (93.1) | 2587 (69.8) | 29 869 (92.9) | 44 102 (90.4) | 334 201 (93.1) | |
Death | |||||||
Death within 30 days, n (%) | 532 (0.6) | 1384 (0.8) | 52 (1.4) | 325 (1) | 346 (0.7) | 2639 (0.7) | < 0.0001 |
Age at death, yr, median (IQR) | |||||||
Alberta | 75 (63–86) | 74 (65–85) | 72 (69–80) | 66 (56–73) | NA | 74 (63–85) | 0.01 |
Ontario | 79 (70–87) | 75 (65–84) | 73 (60–86) | 74 (65–84) | 78 (66–86) | 76 (66–85) | < 0.0001 |
Male, n (%) | 302 (56.8) | 822 (59.4) | 30 (57.7) | 202 (62.2) | 192 (55.5) | 1548 (58.7) | < 0.0001 |
Days to death, median (IQR) | |||||||
Alberta | 8 (3–14) | 9 (4–17) | 12 (4–18) | 9 (3–14) | NA | 9 (4–15) | 0.4 |
Ontario | 11 (6–17) | 12 (7–19) | 16 (11–21) | 13 (6–20) | 10 (4–16) | 12 (6–19) | < 0.0001 |
All-cause hospitalization | |||||||
Hospital admission within 30 days | 3470 (3.8) | 11 552 (6.3) | 295 (8) | 2321 (7.2) | 2618 (5.4) | 20 256 (5.6) | < 0.0001 |
Age at hospitalization, yr, median (IQR) | |||||||
Alberta | 55 (38– 69) | 54 (41–66) | 57 (39–69) | 53 (40–62) | NA | 54 (40–67) | 0.3 |
Ontario | 63 (48–77) | 59 (46–71) | 57 (43–70) | 60 (48–72) | 61 (41–75) | 60 (46–73) | < 0.0001 |
Male, n (%) | 1878 (54.1) | 6284 (54.4) | 169 (57.3) | 1335 (57.5) | 1381 (52.8) | 11 047 (54.5) | < 0.0001 |
Length of stay, d, median (IQR) | |||||||
Alberta | 5 (3–10) | 5 (3–10) | 6 (3–10) | 6 (3–10) | NA | 5 (3–10) | 0.8 |
Ontario | 6 (3–11) | 6 (3–11) | 6 (3–11) | 7 (3–12) | 6 (2–11) | 6 (3–12) | < 0.0001 |
Note: CABG = coronary artery bypass graft, CAD = coronary artery disease, COPD = chronic obstructive pulmonary disease, IQR = interquartile range, MI = myocardial infarction, NA = not available, PCI = percutaneous coronary intervention, TIA = transient ischemic attack.
↵* Cells with values of less than 5 have been suppressed for privacy reasons.